My understanding, there are 190Mil doses of Relenza will be produce in the next year. So being conservative, let say they produce and sell only half 95Mil due to the H1N1 cases are reducing (BTW we are still in Dec, there are still Jan and Feb which is the coldest months, flu may come back).
Royalties calculation: - (95,000,000 x AUD$25/dose) x 7% = AUD$166,250,000 per annum which equates to $41,562,500 per quarter.
What is this about "dwindling Relenza revenue"? Am I missing something here.
BTA Price at posting:
$2.43 Sentiment: None Disclosure: Not Held